Stephen Harding

Monoclonal Gammopathy of Undetermined Significance: An Update for Nephrologists

Levels of sP-selectin and hs-CRP Decrease with Dietary Intervention with Selenium and Coenzyme Q10 Combined: A Secondary Analysis of a Randomized Clinical Trial

Bortezomib as the First Proteasome Inhibitor Anticancer Drug: Current Status and Future Perspectives

Therapeutic Apheresis for Renal Disorders

Free Light Chains in patients with acute coronary syndromes: Relationships to inflammation and renal function

Case 29-2011

The ubiquitin–proteasome system: opportunities for therapeutic intervention in solid tumors

Systemic amyloidosis

Myasthenia gravis

Extracorporeal light chain elimination: high cut-off (HCO) hemodialysis parallel to chemotherapy allows for a high proportion of renal recovery in multiple myeloma patients with dialysis-dependent acute kidney injury

Differential Diagnosis of Glomerular Disease: A Systematic and Inclusive Approach

Early Reduction of Serum-Free Light Chains Associates with Renal Recovery in Myeloma Kidney

IgG4 autoantibodies against muscle-specific kinase undergo Fab-arm exchange in myasthenia gravis patients

Inflammatory bone loss: pathogenesis and therapeutic intervention

Light chains removal by extracorporeal techniques in acute kidney injury due to multiple myeloma: a position statement of the Onconephrology Work Group of the Italian Society of Nephrology

Guidelines on the Use of Therapeutic Apheresis in Clinical Practice – Evidence‐Based Approach from the Writing Committee of the American Society for Apheresis: The Eighth Special Issue

Inhibition of NGLY1 Inactivates the Transcription Factor Nrf1 and Potentiates Proteasome Inhibitor Cytotoxicity

Identification of Amyloidogenic Light Chains Requires the Combination of Serum-Free Light Chain Assay with Immunofixation of Serum and Urine

Role of Plasmapheresis in the Management of Acute Kidney Injury in Patients With Multiple Myeloma: Should We Abandon It?

Paraprotein–Related Kidney Disease: Evaluation and Treatment of Myeloma Cast Nephropathy

Haemodialysis using high cut-off dialysers for treating acute renal failure in multiple myeloma.

Elevated, combined serum free light chain levels and increased mortality: a 5-year follow-up, UK study

Treatment of Acute Renal Failure Secondary to Multiple Myeloma with Chemotherapy and Extended High Cut-Off Hemodialysis

Bortezomib, low‐dose intravenous melphalan, and dexamethasone for patients with relapsed multiple myeloma

Serum free light chain measurement aids the diagnosis of myeloma in patients with severe renal failure

Serum Free‐Light Chain Removal by High Cutoff Hemodialysis: Optimizing Removal and Supportive Care

Quantitative Assessment of Serum and Urinary Polyclonal Free Light Chains in Patients with Chronic Kidney Disease

Estimation of polyclonal IgG4 hybrids in normal human serum